Ceelox receives US patent titled ‘System and Method for Secure and Interactive Dissemination of Information’

Ceelox, Inc. (OTCBB: CELO), (the "Company") proudly announced today that it was issued a patent from the U.S. Patent Office. The patent, U.S. Patent Number 7,945,520 entitled "System and Method for Secure and/or Interactive Dissemination of Information," provides the ability for associating message content with a media element, such as an advertisement, sending the message to a designated recipient, and presenting the media content only after the "unwrapping" of the message through the use of biometric authentication.

The issued patent adds an innovative dimension to online advertising and marketing, allowing advertisers to encrypt unique messages inside electronic images or "wrappers" such as online ads, photographs or artwork, video files, instant messages, and MP3 files. The message is secure; can be delivered via email or through Websites; and gives a user the power to decrypt hidden messages or create their own.

"We are obviously pleased with the U.S. Patent Office's issuance of this patent, which we believe will strengthen our intellectual property protection. This is a significant milestone for our company, and we are very proud of our development team," said Gerry Euston, Ceelox CEO.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.